Pharmaceutical-Grade vs Underground Drugs: Understanding the Risks
In discussions about performance- and image-enhancing drugs, the terms "pharma grade" and "UGL" (underground lab) come up constantly, usually as if the only difference were price. In reality the gap is about much more than cost: it concerns what is actually in the vial, whether it is sterile, and who is accountable if something goes wrong. Our editorial team explains the differences and the risks, without offering any guidance on obtaining or using such substances.
How licensed medicines are made and controlled
A licensed medicine in the UK has been assessed by the Medicines and Healthcare products Regulatory Agency (MHRA) or an equivalent authority. Before approval, the manufacturer must demonstrate quality, safety and efficacy, supported by clinical data and detailed documentation of the manufacturing process.
Production takes place under Good Manufacturing Practice (GMP). This covers everything from the purity of raw materials and the cleanliness of the facility to validated sterilisation of injectable products, batch testing and traceability. Each batch can be traced back to its raw materials and recalled if a defect is found.
After a medicine is on the market, pharmacovigilance systems such as the MHRA Yellow Card scheme collect reports of side effects. Product information is updated when new risks emerge, as happened with warnings about pulmonary oil microembolism for long-acting testosterone undecanoate.
Finally, the supply chain itself is regulated. Licensed wholesalers and pharmacies verify where products come from, and the Falsified Medicines Directive introduced safety features for many prescription medicines in Europe to reduce counterfeits entering legitimate channels.
What "underground" production means
Underground labs produce products outside any regulatory framework. Typically, raw powders are bought from bulk suppliers, often overseas, and then dissolved, filled into vials or pressed into tablets in domestic or makeshift settings.
None of the safeguards described above apply. There is no independent verification of the raw material, no validated sterilisation, no batch testing required by law and no recall system. The label is simply whatever the maker chooses to print.
| Aspect | Licensed pharmaceutical | Underground product |
|---|---|---|
| Raw material | Tested, certified source | Unverified bulk powder |
| Manufacturing | GMP facility, validated processes | Unregulated, often domestic |
| Sterility of injectables | Validated sterilisation and testing | Not guaranteed |
| Content accuracy | Within strict specifications | Variable, sometimes absent or substituted |
| Traceability and recall | Full | None |
| Legal accountability | Manufacturer and regulator | None in practice |
Counterfeit "pharmaceutical" packaging adds another layer of uncertainty. Graham and colleagues described how counterfeiters copy branded packaging so that products appear to come from legitimate manufacturers. Packaging that looks professional is therefore no guarantee of origin or quality.
The World Health Organization has highlighted substandard and falsified medical products as a global public health problem, noting that they can cause treatment failure, toxicity and death across all categories of medicines, not only performance-enhancing drugs.
What laboratory analyses have found
Several research groups have tested seized or submitted performance-enhancing products. A systematic review and meta-analysis by Magnolini and colleagues pooled such analyses and found that a substantial share of products sold as anabolic steroids on the black market were falsified or substandard: wrong substance, no active ingredient, or a dose differing markedly from the label.
Weber and colleagues analysed doping products seized at the Swiss border and also found frequent discrepancies between labelled and actual content. Some products contained a different steroid altogether, and some contained nothing active.
Laboratory tests usually check identity and amount, not sterility. Bacterial contamination, endotoxins and particles may be present even when the active ingredient is correct. Injection of non-sterile products can lead to abscesses, cellulitis and, in severe cases, sepsis.
Hope and colleagues, studying people in the UK who inject image- and performance-enhancing drugs, found evidence of exposure to HIV, hepatitis B and hepatitis C. Shared vials and injecting equipment, as well as contaminated products, are routes of transmission.
Why even "real pharma" carries risk outside medicine
It is a common misconception that obtaining a genuine pharmaceutical product removes the danger. The quality of the product addresses only one part of the risk.
- Dose and duration: non-medical use often involves amounts far above therapeutic doses, for which safety data do not exist.
- Combinations: using several drugs together multiplies effects on the heart, liver and hormones.
- No diagnosis or monitoring: contraindications go unnoticed and early warning signs in blood tests are missed.
- Diversion: genuine-looking products in informal channels may be stolen, expired or improperly stored.
The Endocrine Society statement by Pope and colleagues describes harms associated with performance-enhancing drugs regardless of their source, including cardiomyopathy, accelerated atherosclerosis, infertility, hormonal suppression and psychiatric effects.
In short, pharmaceutical quality reduces some risks, such as contamination and wrong substances, but does not make non-medical use safe. Underground products add uncertainty on top of the inherent risks of the drugs themselves.
The UK legal picture and where to get help
In the UK, anabolic steroids are Class C controlled drugs under the Misuse of Drugs Act 1971. Possession for personal use is not currently an offence, but supply, importation by post or courier and production are. Many other substances discussed in gym circles are prescription-only medicines, and selling them without authorisation is illegal under medicines legislation.
For athletes in tested sport, UK Anti-Doping (UKAD) enforces the WADA Code. Contaminated or mislabelled products do not provide a defence, because athletes are strictly liable for any prohibited substance found in their sample.
Confidential harm-reduction support is available. Many needle and syringe programmes in the UK offer advice, testing for blood-borne viruses and health checks for people who use image- and performance-enhancing drugs, without judgement.
If you experience symptoms such as chest pain, breathlessness, severe headache, a hot and swollen injection site or fever, seek medical help promptly and be honest about what you have taken. Clinicians are there to treat you, not to report you.
Conclusions of the editorial team
Licensed pharmaceuticals are made under strict controls that ensure identity, dose, purity and sterility. Underground products have none of these guarantees, and analyses repeatedly find wrong or missing ingredients.
Even genuine pharmaceuticals carry serious risks when used outside medical supervision, at high doses and in combinations.
The safest choice is not to use these substances. Anyone who does should be aware of harm-reduction services and seek medical help quickly when problems arise.
We also suggest our articles on injection-site infections, blood tests for people who have used anabolic steroids, and how supplement contamination affects tested athletes.
References
- Pope HG Jr, Wood RI, Rogol A, et al. Adverse health consequences of performance-enhancing drugs: an Endocrine Society scientific statement. Endocr Rev. 2014;35(3):341–375.
- Magnolini R, Falcato L, Cremonesi A, Schori D, Bruggmann P. Fake anabolic androgenic steroids on the black market – a systematic review and meta-analysis on qualitative and quantitative analytical results found within the literature. BMC Public Health. 2022;22(1):1371.
- Graham MR, Ryan P, Baker JS, et al. Counterfeiting in performance- and image-enhancing drugs. Drug Test Anal. 2009;1(3):135–142.
- Weber C, Krug O, Kamber M, Thevis M. Qualitative and semiquantitative analysis of doping products seized at the Swiss border. Subst Use Misuse. 2017;52(6):742–753.
- Hope VD, McVeigh J, Marongiu A, et al. Prevalence of, and risk factors for, HIV, hepatitis B and C infections among men who inject image and performance enhancing drugs: a cross-sectional study. BMJ Open. 2013;3(9):e003207.
- World Health Organization. A study on the public health and socioeconomic impact of substandard and falsified medical products. Geneva: WHO; 2017.
